학술논문
Real-world effectiveness and safety of the LAight-therapy in patients with hidradenitis suppurativa.
Document Type
Academic Journal
Author
Strobel A; Institute of Medical Epidemiology, Biostatistics, and Informatics, Faculty of Medicine, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.; Profile Centre of Health Sciences Halle, Faculty of Medicine, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.; Schultheis M; Dept. of Dermatology, University Medical Center, Johannes Gutenberg, University, Mainz, Germany.; Staubach P; Dept. of Dermatology, University Medical Center, Johannes Gutenberg, University, Mainz, Germany.; Grabbe S; Dept. of Dermatology, University Medical Center, Johannes Gutenberg, University, Mainz, Germany.; Mann C; Dept. of Dermatology, University Medical Center, Johannes Gutenberg, University, Mainz, Germany.; Hennig K; Dept. of Dermatology, University Medical Center, Johannes Gutenberg, University, Mainz, Germany.; Szepietowski JC; Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.; Matusiak L; Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.; Krajewski P; Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.; von Stebut E; Department of Dermatology, Faculty of Medicine, University of Cologne, Cologne, Germany.; Garcovich S; Dermatology Outpatient Office Dr. Simone Garcovich, Rome, Italy.; Bayer H; Dermatology Outpatient Office Hautmedizin Bad Soden, Bad Soden, Germany.; Heise M; Profile Centre of Health Sciences Halle, Faculty of Medicine, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.; Institute for Health- and Nursing Science, Faculty of Medicine, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.; Institute of General Practice and Family Medicine, Faculty of Medicine, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.; Podda M; Department of Dermatology, Medical Center Klinikum Darmstadt, Teaching Hospital Goethe-University Frankfurt, Darmstadt, Germany.; Kirschner U; Dermatology Outpatient Office Dr. Uwe Kirschner, Mainz, Germany.; Nikolakis G; Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany.
Source
Publisher: Blackwell Country of Publication: Germany NLM ID: 101164708 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1610-0387 (Electronic) Linking ISSN: 16100379 NLM ISO Abbreviation: J Dtsch Dermatol Ges Subsets: MEDLINE
Subject
Language
English
Abstract
Background and Objectives: Hidradenitis suppurativa (HS)/Acne inversa (Ai) is a chronic debilitating disease with limited therapy options. The device-based LAight therapy was approved in Europe in 2017. The aim of this study was to evaluate the effect of real-world care with at least one treatment with LAight therapy on disease activity and burden in 3,437 patients.
Patients and Methods: Patients were included in the analysis if they had a diagnosis of HS and received at least one treatment. The endpoints Hidradenitis Suppurativa Severity Score System (IHS4), pain on the numeric rating scale (pain-NRS) and Dermatology Life Quality Index (DLQI) were analyzed using a linear mixed model for repeated measures (MMRM) over 26 weeks of care with LAight therapy. Furthermore, responder rates were calculated for all endpoints, and the therapy's safety profile and patient satisfaction were thoroughly examined.
Results: A significant decrease in IHS4, pain-NRS, and DLQI was achieved during 26 weeks of care with LAight. The BMI at baseline had a significant negative effect on therapy response for pain-NRS and DLQI.
Conclusions: This study confirms that LAight therapy leads to satisfactory disease control in all stages of severity and is a valuable addition to the therapeutic repertoire of HS.
(© 2024 The Author(s). Journal der Deutschen Dermatologischen Gesellschaft published by Wiley‐VCH GmbH on behalf of Deutsche Dermatologische Gesellschaft.)
Patients and Methods: Patients were included in the analysis if they had a diagnosis of HS and received at least one treatment. The endpoints Hidradenitis Suppurativa Severity Score System (IHS4), pain on the numeric rating scale (pain-NRS) and Dermatology Life Quality Index (DLQI) were analyzed using a linear mixed model for repeated measures (MMRM) over 26 weeks of care with LAight therapy. Furthermore, responder rates were calculated for all endpoints, and the therapy's safety profile and patient satisfaction were thoroughly examined.
Results: A significant decrease in IHS4, pain-NRS, and DLQI was achieved during 26 weeks of care with LAight. The BMI at baseline had a significant negative effect on therapy response for pain-NRS and DLQI.
Conclusions: This study confirms that LAight therapy leads to satisfactory disease control in all stages of severity and is a valuable addition to the therapeutic repertoire of HS.
(© 2024 The Author(s). Journal der Deutschen Dermatologischen Gesellschaft published by Wiley‐VCH GmbH on behalf of Deutsche Dermatologische Gesellschaft.)